Ionis Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Ionis Pharmaceuticals hat ein Gesamteigenkapital von $315.5M und eine Gesamtverschuldung von $1.3B, was einen Verschuldungsgrad von 405.5% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $2.9B bzw. $2.6B.
Key information
462.5%
Debt to equity ratio
US$1.79b
Debt
| Interest coverage ratio | n/a |
| Cash | US$2.34b |
| Equity | US$386.69m |
| Total liabilities | US$2.60b |
| Total assets | US$2.99b |
Recent financial health updates
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
Mar 18
Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Dec 07Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Aug 03Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
May 05Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?
Jan 20Ionis Pharmaceuticals (NASDAQ:IONS) Could Easily Take On More Debt
Aug 08Recent updates
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
Mar 18Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain
Feb 23Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected
Dec 28Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Dec 07A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Nov 16Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Aug 03Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
May 05Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?
Jan 20Ionis Pharmaceuticals Looks Good For The Long Term
Oct 19Ionis plans for new manufacturing site in California to support pipeline
Oct 13Ionis: 2 Drug Advancements With Potential Firsts
Aug 29Ionis Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Ionis Pharmaceuticals (NASDAQ:IONS) Could Easily Take On More Debt
Aug 08Ionis Pharma: Too Many Programs Have Failed To Produce Confidence
Jun 15Is Ionis Pharmaceuticals (NASDAQ:IONS) Weighed On By Its Debt Load?
Apr 06Ionis Pharmaceuticals: Finding Financial Value In Biotech Research
Mar 27Ionis: At A Show-Me Crossroads
Mar 14Some Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Analysts Just Made A Major Cut To Next Year's Estimates
Feb 25Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Dec 28Ionis Has A Lot Of Upside, I Am Bullish On This Stock
Dec 16Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
Sep 12Ionis: Should One Failure Cause So Much Distress?
Aug 22Financial Position Analysis
Kurzfristige Verbindlichkeiten: IONSDie kurzfristigen Aktiva des Unternehmens ($2.6B) übersteigen seine kurzfristigen Passiva ($404.2M).
Langfristige Verbindlichkeiten: IONSDie kurzfristigen Vermögenswerte des Unternehmens ($2.6B) übersteigen seine langfristigen Verbindlichkeiten ($2.2B).
Debt to Equity History and Analysis
Verschuldungsgrad: IONS über mehr Barmittel verfügt als seine Gesamtverschuldung.
Schulden abbauen: IONSDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 76% auf 405.5% gestiegen.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stabile Start- und Landebahn für Bargeld: IONS auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt.
Vorhersage Cash Runway: Unzureichende Daten, um festzustellen, ob IONS über genügend Cash Runway verfügt, wenn sein freier Cashflow auf der Grundlage historischer Raten weiter wächst oder schrumpft.